Preliminary Communication

Conjugating Prussian blue nanoparticles onto antigen-specific T cells as a combined nanoimmunotherapy

Institute for Biomedical Sciences, The George Washington University, Washington, DC, USA

The Sheikh Zayed Institute for Pediatric Surgical Innovation, Children's National Health System, Washington, DC, USA

Center for Emerging Technologies in Immune Cell Therapy, Children's National Health System, Washington, DC, USA

Search for more papers by this author

Shabnum Patel

Institute for Biomedical Sciences, The George Washington University, Washington, DC, USA

Center for Emerging Technologies in Immune Cell Therapy, Children's National Health System, Washington, DC, USA

Search for more papers by this author

Catherine M Bollard

Institute for Biomedical Sciences, The George Washington University, Washington, DC, USA

Department of Pediatrics, The George Washington University, Washington, DC, USA

Center for Cancer & Immunology Research, Children's National Health System, Washington, DC, USA

Center for Emerging Technologies in Immune Cell Therapy, Children's National Health System, Washington, DC, USA

Search for more papers by this author

Conrad Russell Y Cruz

*Author for correspondence:

E-mail Address: CCruz@childrensnational.org

Institute for Biomedical Sciences, The George Washington University, Washington, DC, USA

Department of Pediatrics, The George Washington University, Washington, DC, USA

Center for Cancer & Immunology Research, Children's National Health System, Washington, DC, USA

Center for Emerging Technologies in Immune Cell Therapy, Children's National Health System, Washington, DC, USA

Search for more papers by this author

Rohan Fernandes

**Author for correspondence:

E-mail Address: RFernand@childrensnational.org

Institute for Biomedical Sciences, The George Washington University, Washington, DC, USA

Department of Pediatrics, The George Washington University, Washington, DC, USA

Department of Radiology, The George Washington University, Washington, DC, USA

The Sheikh Zayed Institute for Pediatric Surgical Innovation, Children's National Health System, Washington, DC, USA

Search for more papers by this author

Published Online:7 Jul 2016https://doi.org/10.2217/nnm-2016-0160

View article

Abstract

Aim: To engineer a novel nanoimmunotherapy comprising Prussian blue nanoparticles (PBNPs) conjugated to antigen-specific cytotoxic T lymphocytes (CTL), which leverages PBNPs for their photothermal therapy (PTT) capabilities and Epstein–Barr virus (EBV) antigen-specific CTL for their ability to traffic to and destroy EBV antigen-expressing target cells. Materials & methods: PBNPs and CTL were independently biofunctionalized. Subsequently, PBNPs were conjugated onto CTL using avidin–biotin interactions. The resultant cell-nanoparticle construct (CTL:PBNPs) were analyzed for their physical, phenotypic and functional properties. Results: Both PBNPs and CTL maintained their intrinsic physical, phenotypic and functional properties within the CTL:PBNPs. Conclusion: This study highlights the potential of our CTL:PBNPs nanoimmunotherapy as a novel therapeutic for treating virus-associated malignancies such as EBV+ cancers.

Keywords:

Papers of special note have been highlighted as: • of interest; •• of considerable interest

References

1 Schutz CA, Juillerat-Jeanneret L, Mueller H, Lynch I, Riediker M. Therapeutic nanoparticles in clinics and under clinical evaluation. Nanomedicine (Lond.) 8(3), 449–467 (2013).
CASGoogle Scholar
2 Rink JS, Plebanek MP, Tripathy S, Thaxton CS. Update on current and potential nanoparticle cancer therapies. Curr. Opin. Oncol. 25(6), 646–651 (2013).
Medline CASGoogle Scholar
3 Swartz MA, Hirosue S, Hubbell JA. Engineering approaches to immunotherapy. Sci. Transl. Med. 4(148), 148rv149 (2012).
Google Scholar
4 Goldberg MS. Immunoengineering: how nanotechnology can enhance cancer immunotherapy. Cell 161(2), 201–204 (2015). • Provides an important overview of how nanotechnology can be combined with immunotherapy for cancer therapy.
Medline CASGoogle Scholar
5 Bear AS, Kennedy LC, Young JK et al. Elimination of metastatic melanoma using gold nanoshell-enabled photothermal therapy and adoptive T cell transfer. PLoS ONE 8(7), e69073 (2013).
Medline CASGoogle Scholar
6 Wang C, Xu L, Liang C, Xiang J, Peng R, Liu Z. Immunological responses triggered by photothermal therapy with carbon nanotubes in combination with anti-CTLA-4 therapy to inhibit cancer metastasis. Adv. Mater. 26(48), 8154–8162 (2014).
Medline CASGoogle Scholar
7 Zhang P, Chiu YC, Tostanoski LH, Jewell CM. Polyelectrolyte multilayers assembled entirely from immune signals on gold nanoparticle templates promote antigen-specific T cell response. ACS Nano 9(6), 6465–6477 (2015).
Medline CASGoogle Scholar
8 Flynn ER, Bryant HC, Bergemann C, Larson RS, Lovato D, Sergatskov DA. Use of a SQUID array to detect T-cells with magnetic nanoparticles in determining transplant rejection. J. Magn. Magn. Mater. 311(1), 429–435 (2007).
Medline CASGoogle Scholar
9 Stephan MT, Moon JJ, Um SH, Bershteyn A, Irvine DJ. Therapeutic cell engineering with surface-conjugated synthetic nanoparticles. Nat. Med. 16(9), 1035–1041 (2010). •• Demonstrates how cell-nanoparticle constructs can be used for enhanced cell therapy in vivo
Medline CASGoogle Scholar
10 Swiston AJ, Gilbert JB, Irvine DJ, Cohen RE, Rubner MF. Freely suspended cellular “backpacks” lead to cell aggregate self-assembly. Biomacromolecules 11(7), 1826–1832 (2010).
Medline CASGoogle Scholar
11 Polak R, Lim RM, Beppu MM, Pitombo RN, Cohen RE, Rubner MF. Liposome-loaded cell backpacks. Adv. Healthc. Mater. 4(18), 2832–2841 (2015).
Medline CASGoogle Scholar
12 Hoffman HA, Chakarbarti L, Dumont MF, Sandler AD, Fernandes R. Prussian blue nanoparticles for laser-induced photothermal therapy of tumors. RSC Adv. 4(56), 29729–29734 (2014). • Demonstrates the synthesis and use of Prussian blue nanoparticles for tumor therapy in vivo.
CASGoogle Scholar
13 Dumont MF, Hoffman HA, Yoon PR et al. Biofunctionalized gadolinium-containing prussian blue nanoparticles as multimodal molecular imaging agents. Bioconjug. Chem. 25(1), 129–137 (2014).
Medline CASGoogle Scholar
14 Vojtech JM, Cano-Mejia J, Dumont MF, Sze RW, Fernandes R. Biofunctionalized prussian blue nanoparticles for multimodal molecular imaging applications. J. Vis. Exp. (98), e52621 (2015).
MedlineGoogle Scholar
15 Dumont MF, Yadavilli S, Sze RW, Nazarian J, Fernandes R. Manganese-containing Prussian blue nanoparticles for imaging of pediatric brain tumors. Int. J. Nanomedicine 9, 2581–2595 (2014).
Medline CASGoogle Scholar
16 Bollard CM. Improving T-cell therapy for Epstein–Barr virus lymphoproliferative disorders. J. Clin. Oncol. 31(1), 5–7 (2013).
Medline CASGoogle Scholar
17 Bollard CM, Aguilar L, Straathof KC et al. Cytotoxic T lymphocyte therapy for Epstein–Barr virus+ Hodgkin's disease. J. Exp. Med. 200(12), 1623–1633 (2004). • Describes the generation of EBV antigen-specific CTL.
Medline CASGoogle Scholar
18 Volz HG. Pigments, Inorganic. Ullumann's Encyclopedia of Industrial Chemistry. Wiley (2006).
Google Scholar
19 Jaiswal JK, Mattoussi H, Mauro JM, Simon SM. Long-term multiple color imaging of live cells using quantum dot bioconjugates. Nat. Biotechnol. 21(1), 47–51 (2003). •• Provides the scheme for robustly bioconjugating nanoparticles onto cells.
Medline CASGoogle Scholar
20 Goldman ER, Balighian ED, Mattoussi H et al. Avidin: a natural bridge for quantum dot-antibody conjugates. J. Am. Chem. Soc. 124(22), 6378–6382 (2002).
Medline CASGoogle Scholar
21 Choi MR, Bardhan R, Stanton-Maxey KJ et al. Delivery of nanoparticles to brain metastases of breast cancer using a cellular Trojan horse. Cancer Nanotechnol. 3(1–6), 47–54 (2012).
Medline CASGoogle Scholar
22 Arina A, Bronte V. Myeloid-derived suppressor cell impact on endogenous and adoptively transferred T cells. Curr. Opin. Immunol. 33, 120–125 (2015).
Medline CASGoogle Scholar
23 Arina A, Corrales L, Bronte V. Enhancing T cell therapy by overcoming the immunosuppressive tumor microenvironment. Semin. Immunol. 28(1), 54–63 (2016).
Medline CASGoogle Scholar
24 Munn DH, Bronte V. Immune suppressive mechanisms in the tumor microenvironment. Curr. Opin. Immunol. 39, 1–6 (2016).
Medline CASGoogle Scholar
25 Burga RA, Thorn M, Point GR et al. Liver myeloid-derived suppressor cells expand in response to liver metastases in mice and inhibit the anti-tumor efficacy of anti-CEA CAR-T. Cancer Immunol. Immunother. 64(7), 817–829 (2015).
Medline CASGoogle Scholar

Vol. 11, No. 14

Supplemental Materials

Metrics

Downloaded 305 times

History

Published online 7 July 2016

Published in print July 2016

Information

Keywords

Acknowledgements

The authors acknowledge the Sheikh Zayed Institute for Pediatric Surgical Innovation at Children's National Health System and the Institute of Biomedical Sciences at George Washington University, where RAB is a doctoral student.

Disclaimer

The contents of this report contents are solely the responsibility of the authors and do not necessarily represent the official views of the National Center for Advancing Translational Sciences or the National Institutes of Health.

Financial & competing interests disclosure

This work was also supported by Awards UL1TR000075 and KL2TR000076 from the NIH National Center for Advancing Translational Sciences. This work is covered by pending patents. R Fernandes is listed as an inventor on a pending patent US20140271487 A1. RA Burga, CM Bollard, CRY Cruz and R Fernandes are listed as inventors on a United States provisional patent application (application number in process). The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

No writing assistance was utilized in the production of this manuscript.

Ethical conduct of research

The authors state that they have obtained appropriate institutional review board approval or have followed the principles outlined in the Declaration of Helsinki for all human or animal experimental investigations. In addition, for investigations involving human subjects, informed consent has been obtained from the participants involved.

PDF download